Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results

Q3 2024 ADHD Portfolio net revenue up 49% compared to Q3 2023Q3 2024 adjusted EBITDA 1 improved by $7.0 million compared to Q3 2023TTM March 2024 operating income of $7.3 million for the Rx BusinessTTM March 2024 companywide adjusted EBITDA of positive $15.4 millionTTM March 2024 adjusted EBITDA of positive $17.1 mi...

Related Keywords

United States ,Denver ,Colorado ,Texas ,Grand Prairie ,Mark Oki ,Roger Weiss ,Aytu Rxconnect ,Josh Disbrow ,Company Rx Business ,Consumer Health Segment ,Company Or Aytu Nasdaq ,Aytu Biopharma Inc ,Exchange Commission ,Securities Exchange ,Consumer Health ,Aytu Biopharma ,Health Segment ,Chief Executive Officer ,Pediatric Portfolio ,Trailing Twelve Month ,Full Prescribing Information ,Securities Act ,Securities Exchange Act ,Annual Report ,Chief Financial ,Consolidated Statements ,Net Loss ,Three Months Ended March ,Trailing Twelve Month Net Income ,Three Months ,